Clinical trials: Multiple Sclerosis (MS) Relapsing Remitting, open to volunteers
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Home Based Functional Balance Intervention for Multiple Sclerosis
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- HomeFBIinMS (NCT07355387)
- Testing
- Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois at Chicago
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Multiple Sclerosis (MS) - Relapsing-remitting
Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is a chronic neurological disease associated with reduced muscle strength, impaired mobility, increased fatigue, and deterioration in muscle morphology.
- Trial name
- RRMS-BFR (NCT07645937)
- Testing
- Blood Flow Restriction Training, Low-Load Exercise Program
- Volunteers
- 30 people
- Sponsor
- Hanifi Bal
Relapsing Remitting Multiple Sclerosis (RRMS)
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context…
- Trial name
- ELIOS (NCT06733922)
- Testing
- ETNATM-ProgMS
- Where
- 14 sites in Canada
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS) Relapsing Remitting
A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis
This multicenter, randomized, open-label clinical trial aims to evaluate the efficacy and safety of taurine as an adjunctive therapy to standard disease-modifying treatments (DMTs) in patients with multiple sclerosis (MS).
- Trial name
- NCT07263607
- Testing
- DMTs + taurine, DMTs
- Volunteers
- 80 people
- Sponsor
- Sichuan Academy of Medical Sciences
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery
The goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function.
- Trial name
- NCT06641271
- Testing
- Closed Loop Trans-Auricular Vagus Nerve Stimulation System
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis (MS) Relapsing Remitting
Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis
The purpose of this study is to assess the immediate effects of a commercially available non-FDA regulated powered hip flexion assist device (Hypershell X, Shenzhen, China) on walking ability in persons with MS.
- Trial name
- NCT07724093
- Testing
- Powered Hip Flexion Orthosis (Hypershell X)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Dayton
PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting
Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
Glucosinolates (GLs) are phytocompounds mainly found in the Cruciferae (Brassicacea) and Moringa oleifera plants. The hydrolysis of GLs by myrosinase led to the production of isothiocyanate (ITCs).
- Conditions
- PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting, Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases
- Trial name
- GRA-MYR-ND (NCT07360977)
- Testing
- bioactivated GRA for adult patients, bioactivated GRA for pediatric patients
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis.
- Trial name
- MS-ACT (NCT06567197)
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy…
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- BEAT-MS (NCT04047628)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Where
- 23 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing Remitting Multiple Sclerosis (RRMS)
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans.
- Trial name
- iPROACT-MS (NCT07318129)
- Testing
- Indole-3-propionic acid (IPA)
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Rationale: Ocrelizumab is widely and effectively used to treat relapsing multiple sclerosis (RMS). Phase II studies and data from large patient cohorts indicate that rituximab, another anti-CD20 monoclonal antibody, is probably…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
- Trial name
- Noisy Rebels (NCT05834855)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Sexual Dysfunction in Women With Multiple Sclerosis (MS)
Sexual dysfunction in women with multiple sclerosis (MS) is an important yet often overlooked problem. The primary objective of this study is to investigate the prevalence of sexual dysfunction in female patients diagnosed with…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Fatigue in Multiple Sclerosis, Sexual Disfunction
- Trial name
- MS (NCT07193823)
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Ege University
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired "selfie" videos in people with multiple sclerosis.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis)
- Trial name
- NCT07222618
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- ReVIVE (NCT05359653)
- Testing
- Clemastine Fumarate
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS)
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3.
- Conditions
- Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary-progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- INsIDER (NCT05177523)
- Testing
- MRI, Neurocognitive examination for healthy subjects, blood sampling
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis (MS) - Relapsing-remitting
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity.
- Trial name
- MoMo-NfL (NCT07292480)
- Testing
- Monthly pNfL monitoring
- Where
- 2 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06526364
- Testing
- All participants will be asked to provide data and samples for collection and analysis.
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis and the Effects of Ketogenic Diet Therapy
Multiple sclerosis (MS) is an inflammatory and immune-mediated neurological disease with multifactorial etiology. The specific etiopathogenetic mechanisms of MS are still unknown but it is clear that it results from a combination…
- Trial name
- NCT06715436
- Testing
- Mediterranean Diet, Ketogenic Diet, Control group
- Where
- Italy
- Volunteers
- 111 people
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation